July 3, 2013 – An interventional x-ray system with live-image
guidance and featuring low-dose settings received 510(k) clearance from the United
States (U.S.) Food and Drug Administration (FDA).
Philips announced that will now market its AlluraClarity live image
guidance system in the U.S. Philips’ AlluraClarity system with its ClarityIQ technology is designed to provide high-quality imaging for a comprehensive
range of clinical procedures, achieving high visibility at low x-ray dose
levels for patients of all sizes. To reflect the cost pressures that modern
hospitals and health systems face, ClarityIQ technology will also be available
as an upgrade for the majority of Philips’ installed base of monoplane and
biplane interventional x-ray systems.
“All patients treated via x-ray guided interventions benefit from the
advantage of low radiation exposure, but it is especially important when you
are treating patients who have to undergo lengthy and complex procedures,” said
Dr. Marco van Strijen, interventional radiologist at the St. Antonius Hospital
Utrecht/Nieuwegein, the Netherlands. “We have been using Philips’ AlluraClarity
system for more than a year now and have really grown to appreciate the low
dose settings. This technology is making a difference where it really
AlluraClarity’s low x-ray dose settings are designed to help clinicians
better manage their patients’ and their own exposure to x-ray radiation. This
achievement is the result of a multi-year development program that formed part
of Philips’ continuous investment in healthcare R&D, totaling EUR 803
million in 2012.
For more information: www.philips.us/AlluraClarity and www.appliedradiology.com